Related Experiment Videos
Fetal serum beta2-microglobulin predicts postnatal renal function in bilateral uropathies
M Dommergues1, F Muller, S Ngo
1Maternité, Hôpital A. Béclère, and Biochimie, Hôpital A. Paré Paris, France.
Kidney International
|July 8, 2000
Summary
Fetal serum beta2-microglobulin (beta2m) can predict a baby's kidney function after birth. This marker helps identify infants with uropathy who may survive with impaired renal function.
Area of Science:
- Perinatology
- Nephrology
- Biochemistry
Background:
- Prenatal diagnosis of fetal uropathies is critical for evaluating postnatal renal function.
- Ultrasound can detect severe renal failure but struggles to predict survival with impaired function.
- Fetal serum beta2-microglobulin (beta2m) is a potential biomarker for glomerular filtration and postnatal renal outcomes.
Purpose of the Study:
- To assess fetal serum beta2-microglobulin as a predictor of postnatal renal function in cases of fetal bilateral uropathy.
- To correlate fetal beta2m levels with postnatal serum creatinine in live-born infants with uropathy.
Main Methods:
- Assayed fetal serum beta2-microglobulin (beta2m) in 61 fetuses with bilateral or low obstructive uropathy, 17 with renal agenesis, and 74 controls.
- Correlated fetal beta2m levels with postnatal serum creatinine in live births.
Main Results:
- Fetal beta2m levels were elevated in renal agenesis and uropathy cases compared to controls.
- A significant positive correlation (r2 = 0.91) was found between fetal beta2m and postnatal serum creatinine in live-born infants with uropathy.
- Fetal beta2m levels below 5 mg/L were associated with favorable postnatal renal function (creatinine ≤50 micromol/L).
Conclusions:
- Fetal serum beta2-microglobulin serves as a valuable marker for predicting postnatal renal function.
- Beta2m levels can help predict postnatal serum creatinine in infants with bilateral or low obstructive uropathy.